Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

Medicine, Rheumatology and Immunology, Neurology,
Myelin oligodendrocyte glycoprotein antibody-associated disease   Oral corticosteroids   Time to relapse   Dosage   Taper duration  

This is a multicenter retrospective cohort study on the impact of oral corticosteroid dosage and tapering duration on the time to first relapse in patients with initial presentation of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Background: MOGAD is a unique antibody-associated demyelinating disease. In both children an...